A5036235601- Celiac Disease Research and Management
- Microscopic Colitis
- T-cell and B-cell Immunology
- Galectins and Cancer Biology
- Monoclonal and Polyclonal Antibodies Research
- Cardiac and Coronary Surgery Techniques
- Cardiac Fibrosis and Remodeling
- Cardiac Ischemia and Reperfusion
- Immune Cell Function and Interaction
- Gastrointestinal motility and disorders
University of Oslo
2019-2024
Coeliac UK
2022
Oslo University Hospital
2021
Abstract In coeliac disease (CeD), the epithelial lining (EL) of small intestine is severely damaged through a complex auto-inflammatory response that results in intraepithelial lymphocytes (IELs) attacking cells (ECs). To better understand changes occurring EL CeD, including after initiation gluten-free diet, and regulatory mechanisms affect mucosal homeostasis, we investigated ECs IELs CeD duodenal using RNA-seq eQTL analysis on predicted cell types. The study included 82 biopsies from...
Background Increasing efforts are being put into new treatment options for coeliac disease (CeD), a chronic disorder of the small intestine induced by gluten. Interleukin‐2 (IL‐2) and gluten‐specific CD4 + T cells increase in blood after four hours six days, respectively, following gluten challenge CeD patients. These responses unique to not seen controls. We aimed evaluate different markers reflecting recall response exposure that may be used monitor therapy. Methods patients on gluten‐free...
Gut intraepithelial γδ and CD8+ αβ T lymphocytes have been connected to celiac disease (CeD) pathogenesis. Based on the previous observation that activated (CD38+), gut-homing (CD103+) cells increase in blood upon oral gluten challenge, we wanted shed light pathogenic involvement of these by examining clonal relationship between gut during exposure. Of 20 gluten-challenged CeD patients, 8 10 had (CD38+CD103+) cells, respectively, while 16 gluten-specific CD4+ cells. We obtained TCR sequences...
Abstract Gluten‐specific CD4 + T cells being drivers of celiac disease (CeD) are obvious targets for immunotherapy. Little is known about how cell markers harnessed T‐cell‐directed therapy can change with time and upon activation in CeD other autoimmune conditions. In‐depth characterization gluten‐specific CeD‐associated (CD38 CD103 ) CD8 γδ blood treated patients undergoing a 3 day gluten challenge reported. The phenotypic profile changes profoundly exposure the adopt untreated (CD147 ,...